Evidence map›Paper›PMID 37436547›Full record

ArticleApplied biochemistry and biotechnology2024

In-Vitro Cytotoxic, Antiproliferative and Apoptotic Activity of Siddha Formulation Nandhi Mezhugu (NM) Against Hela Cell Line.

N Sabari Girija, B Neethi, L Sakthimanipriya, M A Sinekha, P Shanmugapriya, R Meenakumari

Abstract read
PubMed Publisher
In one paragraph

Article in Applied biochemistry and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

N Sabari GirijaNational Institute of Siddha, Tambaram Sanatorium, Chennai, Tamil Nadu, 600047, India. drgirijakrish@gmail.com.ORCID http://orcid.org/0000-0001-5179-9922
B NeethiNational Institute of Siddha, Tambaram Sanatorium, Chennai, Tamil Nadu, 600047, India.
L SakthimanipriyaNational Institute of Siddha, Tambaram Sanatorium, Chennai, Tamil Nadu, 600047, India.
M A SinekhaNational Institute of Siddha, Tambaram Sanatorium, Chennai, Tamil Nadu, 600047, India.
P ShanmugapriyaDepartment of Nanju Maruthuvam, National Institute of Siddha, Tambaram Sanatorium, Chennai, Tamil Nadu, India.
R MeenakumariNational Institute of Siddha, Tambaram Sanatorium, Chennai, Tamil Nadu, 600047, India.
Government Hospital of Thoracic Medicine · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer is the most common cancer among women of childbearing age. Nandhi Mezhugu is a Siddha herbo-mineral drug widely used to treat cancer. Due to a lack of scientific evidence, the present study was intended to evaluate the anti cancer activity of Nandhi Mezhugu in the HeLa cell line. The cells were cultured in Dulbecco's modified Eagle medium, then treated with different concentrations of the test drug (10 to 200 µg/ml). The anti proliferative activity of the drug was evaluated using an MTT assay. Cell apoptosis and cell cycle were measured by flow cytometry and typical nuclear changes of apoptotic processes were observed under the microscope using the dual acridine orange/ethidium bromide fluorescent staining method. The study result showed that the percentage of cell viability decreased with an increase in the concentration of the test drug. The MTT assay data showed that the test drug Nandhi Mezhugu had the antiproliferative effect on cervical cancer cells with IC

Indexed as

Antineoplastic AgentsUterine Cervical NeoplasmsApoptosisCell ProliferationFemaleHeLa CellsHumansAntineoplastic AgentsAnti-cancerCervical cancerHeLa cell lineMTT assayNandhi Mezhugu

Identifiers

PMID37436547
OpenAlexW4383998648

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.